Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
Florent Malard, Arthur Bobin, Myriam Labopin, Lionel Karlin, Laurent Frenzel, Murielle Roussel, Marguerite Vignon, Sophie Godet, Thomas Chalopin, Perrine Moyer, Émilie Chalayer, Frédérique Orsini Piocelle, Clara Mariette, Carolyne Croizier, Claudine Sohn, Mamoun Dib, Ronan Le Calloch, Nadia Ali‐Ammar, Marion Loirat, Omar Benbrahim, Alexandre Payssot, Adrien Trebouet, Aurore Perrot, Xavier Leleu, Mohamad Mohty
Abstract
Elranatamab is a humanized, bispecific antibody that targets B-cell maturation antigen (BCMA) on multiple myeloma (MM) cells and CD3 on T cells, with the aim of inducing T cell-mediated cytolysis of the MM cells [ 1 , 2 ]. Elranatamab was approved as monotherapy for relapsed-refractory MM (RRMM) based on the phase II MagnetisMM-3 (NCT04649359) registrational study [ 3 ]. Here, we report clinical outcomes with standard-of-care elranatamab in a real-world RRMM population as part of the French compassionate use program.